Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies

Figure 3

Efficacy study in patient-derived NSCLC xenograft models. Tumor-bearing nude mice were treated with either vehicle control or gefitinib at 100 mg/kg orally daily dosing for 1 ~ 3 weeks based on tumor growth rates in different patient-derived NSCLC xenograft models when tumors reached 150 ~ 250 mm3 post implantation. Genetic aberrations within each of the models (A-F) are labeled in the graph title. Within the models, EGFR, KRAS, MET and FGFR1 are wild-type and non-amplified unless otherwise stated in the graph title.

Back to article page